Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2025-07-16 Board/Management Inform…
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Appointment of Senior Management Personnel
Board/Management Information Classification · 95% confidence The document is a formal communication dated 16th July 2025 from Sanofi India Limited to stock exchanges (BSE and NSE) reporting the outcome of a Board Meeting held on the same day. The key contents include the appointment of an Interim Managing Director and a new Head of Regulatory Affairs, both senior management changes. It also announces a new exclusive distribution agreement with Emcure Pharmaceuticals. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which governs disclosure of material events including management changes. The document is not a full financial report, earnings release, or audit report. It is not a proxy statement or voting result. It is not a regulatory filing in the sense of certifications or miscellaneous filings, but a formal announcement of board decisions. The primary focus is on management appointments and business agreements approved by the Board. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (12,884 characters) and detailed content support this classification with high confidence.
2025-07-16 English
Appointment
Board/Management Information Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Sanofi India Limited dated 16th July 2025. It informs about the outcome of a Board meeting where key management appointments were approved: the appointment of an Interim Managing Director and a new Head of Regulatory Affairs. It also includes a press release about a new exclusive distribution agreement. The document references compliance with SEBI Listing Regulations and provides detailed profiles of the appointees. There are no financial statements or financial performance data included. The content focuses on changes in senior management and related disclosures as required by regulatory authorities. Therefore, this document fits the category of Board/Management Information (MANG). The document length (12,884 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Hence, the classification is MANG with high confidence.
2025-07-16 English
Appointment of Mr. Rachid Ayari as the Interim Managing Director
Board/Management Information Classification · 100% confidence The document is a formal communication dated 16th July 2025 from Sanofi India Limited to stock exchanges (BSE and NSE) reporting the outcome of a Board Meeting held on the same day. The key contents include the appointment of an Interim Managing Director and a new Head of Regulatory Affairs, both senior management changes. It also announces a new exclusive distribution agreement with Emcure Pharmaceuticals. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events including management changes. The document is not a full financial report, earnings release, or audit report. It is not a proxy statement or voting result. It is not a regulatory filing in the sense of certifications or miscellaneous filings, but a formal announcement of board decisions and management appointments. The presence of detailed appointment information and profiles confirms it is a Board/Management Information filing. The length (over 12,000 characters) and detailed content confirm it is not a brief announcement or report publication notice. Therefore, the document fits the category of Board/Management Information (MANG).
2025-07-16 English
Outcome of Board Meeting
Board/Management Information Classification · 100% confidence The document is a formal communication dated 16th July 2025 from Sanofi India Limited to stock exchanges (BSE and NSE) reporting the outcome of a Board Meeting held on the same day. The key contents include the appointment of an Interim Managing Director and a new Head of Regulatory Affairs, both senior management changes. It also announces a new exclusive distribution and promotion agreement with Emcure Pharmaceuticals. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events including changes in management. The document is not a full financial report, earnings release, or audit report. It is not a proxy statement or voting result announcement. It is not a regulatory filing in the sense of certifications or miscellaneous filings, but a formal announcement of board decisions regarding management appointments and a business agreement. The length (over 12,000 characters) and detailed profiles of appointees confirm it is not a brief announcement or report publication notice. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-07-16 English
Please find enclosed Outcome of Board Meeting dated 16th July 2025.
Board/Management Information Classification · 100% confidence The document is a formal communication dated 16th July 2025 from Sanofi India Limited to stock exchanges (BSE and NSE) reporting the outcome of a Board Meeting held on the same day. The key contents include the appointment of an Interim Managing Director and a new Head of Regulatory Affairs, both senior management changes, and approval of a distribution agreement. The document references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events including changes in directors or key managerial personnel. The document includes detailed annexures about the appointments and a press release about the distribution agreement. There are no financial statements or financial performance data presented. The document is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting result announcement. The primary focus is on management changes and a business agreement approval by the Board. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (12,884 characters) and detailed content confirm it is not a brief announcement or a report publication notice.
2025-07-16 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, provided by the Registrar and Share Transfer Agent (RTA) for the period ended 30th June 2025. It confirms the dematerialisation of securities and related compliance activities. The document is a formal certification letter addressed to stock exchanges and does not contain financial statements, management discussion, or detailed report content. It is primarily an attestation or confirmation letter related to regulatory compliance. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as a financial report or other specific filing types.
2025-07-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.